scholarly journals Automatic Breast Tumor Diagnosis in MRI Based on a Hybrid CNN and Feature-Based Method Using Improved Deer Hunting Optimization Algorithm

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Weitao Ha ◽  
Zahra Vahedi
Keyword(s):  
Breast Cancer ◽  
Optimization Algorithm ◽  
Breast Tumor ◽  
Cell Structure ◽  
Tumor Diagnosis ◽  
Breast Cancer Patients ◽  
Deer Hunting ◽  
Performance Indexes ◽  
Feature Based ◽  
Cell Changes

Breast cancer is an unusual mass of the breast texture. It begins with an abnormal change in cell structure. This disease may increase uncontrollably and affects neighboring textures. Early diagnosis of this cancer (abnormal cell changes) can help definitively treat it. Also, prevention of this cancer can help to decrease the high cost of medical caring for breast cancer patients. In recent years, the computer-aided technique is an important active field for automatic cancer detection. In this study, an automatic breast tumor diagnosis system is introduced. An improved Deer Hunting Optimization Algorithm (DHOA) is used as the optimization algorithm. The presented method utilized a hybrid feature-based technique and a new optimized convolutional neural network (CNN). Simulations are applied to the DCE-MRI dataset based on some performance indexes. The novel contribution of this paper is to apply the preprocessing stage to simplifying the classification. Besides, we used a new metaheuristic algorithm. Also, the feature extraction by Haralick texture and local binary pattern (LBP) is recommended. Due to the obtained results, the accuracy of this method is 98.89%, which represents the high potential and efficiency of this method.

scholarly journals Investigating New Therapeutic Strategies Targeting Hyperinsulinemia's Mitogenic Effects in a Female Mouse Breast Cancer Model

Endocrinology ◽  
2013 ◽  
Vol 154 (5) ◽  
pp. 1701-1710 ◽  
Author(s):  
Ran Rostoker ◽  
Keren Bitton-Worms ◽  
Avishay Caspi ◽  
Zila Shen-Orr ◽  
Derek LeRoith
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Breast Tumor ◽  
Experimental Studies ◽  
Tumor Development ◽  
Treated Group ◽  
Tumor Growth Rate ◽  
Breast Cancer Patients ◽  
Mitogenic Effect

Abstract Epidemiological and experimental studies have identified hyperinsulinemia as an important risk factor for breast cancer induction and for the poor prognosis in breast cancer patients with obesity and type 2 diabetes. Recently it was demonstrated that both the insulin receptor (IR) and the IGF-IR mediate hyperinsulinemia's mitogenic effect in several breast cancer models. Although IGF-IR has been intensively investigated, and anti-IGF-IR therapies are now in advanced clinical trials, the role of the IR in mediating hyperinsulinemia's mitogenic effect remains to be clarified. Here we aimed to explore the potential of IR inhibition compared to dual IR/IGF-IR blockade on breast tumor growth. To initiate breast tumors, we inoculated the mammary carcinoma Mvt-1 cell line into the inguinal mammary fat pad of the hyperinsulinemic MKR female mice, and to study the role of IR, we treated the mice bearing tumors with the recently reported high-affinity IR antagonist-S961, in addition to the well-documented IGF-IR inhibitor picropodophyllin (PPP). Although reducing IR activation, with resultant severe hyperglycemia and hyperinsulinemia, S961-treated mice had significantly larger tumors compared to the vehicle-treated group. This effect maybe secondary to the severe hyperinsulinemia mediated via the IGF-1 receptor. In contrast, PPP by partially inhibiting both IR and IGF-IR activity reduced tumor growth rate with only mild metabolic consequences. We conclude that targeting (even partially) both IR and IGF-IRs impairs hyperinsulinemia's effects in breast tumor development while simultaneously sparing the metabolic abnormalities observed when targeting IR alone with virtual complete inhibition.

Micropallet Technology for Investigating Tumor Cellular Profiles and Analysis of Rare Cell Subsets

2008 ◽  
Author(s):  
Nicholas M. Gunn ◽  
Mark Bachman ◽  
Edward L. Nelson ◽  
G.-P. Li
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Patients ◽  
Invasive Breast Cancer ◽  
Breast Tumor ◽  
The United States ◽  
Therapeutic Strategies ◽  
Cellular Heterogeneity ◽  
Breast Cancer Patients ◽  
Critical Limits

Rationally designed, individualized therapeutic strategies have long been a desired objective for breast cancer patients and clinicians as an estimated 178,480 new cases of invasive breast cancer will be diagnosed among women in the United States this year and over 40,000 women are expected to die from the disease. [1] The increasing appreciation of breast tumor cellular heterogeneity raises fundamental questions as to the relative contributions of cellular subsets to the biologic behavior of an individual patient’s tumor. [2] As such, it has become increasingly clear that in many cases, an individualized strategy for the treatment of breast cancer would be of great benefit, and that the ability to isolate relevant cellular subsets from the main tumor population is one of the critical limits to accomplishing this goal.

scholarly journals Clinical value of peripheral blood M2/M1 like monocyte ratio in the diagnosis of breast cancer and the differentiation between benign and malignant breast tumors

2019 ◽  
Author(s):  
Mustafa Fadhil ◽  
Omar Abdul- Rasheed ◽  
Manwar Al-Naqqash
Keyword(s):  
Breast Cancer ◽  
Tumor Progression ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Tumor ◽  
Healthy Subjects ◽  
Breast Tumors ◽  
Breast Cancer Patients ◽  
Cancer Tumor ◽  
Malignant Breast

Background: During tumor progression, circulating monocytes and macrophages are actively recruited into tumors where they alter the tumor microenvironment to accelerate tumor progression. In response to multiple microenvironmental signals from the tumor and stromal cells, macrophages change their functional phenotypes. Based on their function, macrophages are commonly classified into both, classical M1 and alternative M2 macrophages. M2-like tumor-associated macrophages promote breast tumor growth and survival, and may migrate into the peripheral blood. However, the level of circulating M2/M1-like monocyte ratio in the peripheral blood of breast cancer patients has not been yet clarified. Aim: To compare peripheral blood M2/M1 monocyte ratio among breast cancer patients, benign breast tumor patients and healthy subjects. Also, to investigate the role of peripheral blood M2/M1 monocyte ratio as a circulating breast cancer tumor marker and to asses the validity of this marker in differentiation between benign and malignant breast tumors. Methods: Flow cytometry technique was used to determine the peripheral blood M2/M1 monocyte ratio in three groups of subjects, i.e. 45 patients with breast cancer, 40 patients with benign breast tumor, and 40 healthy subjects as a control group. The results of carbohydrate antigen15-3 (CA15-3) determination were analyzed comparatively. Results: The peripheral blood M2/M1 monocyte ratio in patients with breast cancer (0.27±0.1) was significantly higher (P<0.001) than that in healthy subjects (0.07±0.05) and than in benign tumor subjects (0.08±0.04). The area under the receiver operating characteristic (ROC) curve of peripheral blood M2/M1 monocyte ratio determination was significantly higher (P≤0.001) than that of CA15-3 levels. Conclusion: M2/M1-like monocyte ratio is of a high diagnostic value for breast cancer and is a promising differentiating marker between benign and breast cancer tumor groups.

scholarly journals Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Heng-Huan Lee ◽  
Ying-Nai Wang ◽  
Wen-Hao Yang ◽  
Weiya Xia ◽  
Yongkun Wei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Tumor ◽  
Cell Communication ◽  
Tissue Microarrays ◽  
Stem Cell Marker ◽  
Tyrosine Kinase Receptor ◽  
Tumor Initiation ◽  
Breast Cancer Patients ◽  
Extracellular Rna ◽  
Breast Tumor Tissue

AbstractHuman ribonuclease 1 (hRNase 1) is critical to extracellular RNA clearance and innate immunity to achieve homeostasis and host defense; however, whether it plays a role in cancer remains elusive. Here, we demonstrate that hRNase 1, independently of its ribonucleolytic activity, enriches the stem-like cell population and enhances the tumor-initiating ability of breast cancer cells. Specifically, secretory hRNase 1 binds to and activates the tyrosine kinase receptor ephrin A4 (EphA4) signaling to promote breast tumor initiation in an autocrine/paracrine manner, which is distinct from the classical EphA4-ephrin juxtacrine signaling through contact-dependent cell-cell communication. In addition, analysis of human breast tumor tissue microarrays reveals a positive correlation between hRNase 1, EphA4 activation, and stem cell marker CD133. Notably, high hRNase 1 level in plasma samples is positively associated with EphA4 activation in tumor tissues from breast cancer patients, highlighting the pathological relevance of the hRNase 1-EphA4 axis in breast cancer. The discovery of hRNase 1 as a secretory ligand of EphA4 that enhances breast cancer stemness suggests a potential treatment strategy by inactivating the hRNase 1-EphA4 axis.

scholarly journals Human Papillomavirus Is Associated with Breast Cancer in the North Part of Iran

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Afsaneh Sigaroodi ◽  
Seyed Alireza Nadji ◽  
Farshad Naghshvar ◽  
Rakhshandeh Nategh ◽  
Habib Emami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Tumor ◽  
Hpv Infection ◽  
Test Results ◽  
Breast Cancer Patients ◽  
Hpv Dna ◽  
The North ◽  
North Part ◽  
Reference Sequences ◽  
High Risk Hpv

We have analyzed the possible relevance of HPV infection for breast cancer risk among Iranian women from north part of Iran. Among women with breast cancer, 25.9% had positive test results for HPV DNA in breast tumor samples in contrast to 2.4% of women with noncancer status (P=0.002). The infection of HPV has increased the risk of breast cancer (OR 14.247; 95% CI 1.558–130.284,P=0.019). The high-risk HPV genotypes (types 16 and 18) in samples of breast cancer patients were the predominant types (53.34%). Other genotypes detected in breast cancer were HPV-6, HPV-11, HPV-15, HPV-23, and HPV-124, and one isolate could not be genotyped compared to HPV reference sequences. While the sole detected HPV in control specimens was HPV-124. Our study reveals that HPV infection and age are the risk factors in breast cancer development in the north part of Iran.

Sign in / Sign up

Export Citation Format

Share Document